In this chapter the cutaneous manifestations of malignant and benign haematological disease are reviewed, as well as skin disorders associated with primary and acquired immunodeficiency. The vast array of skin manifestations associated with disorders of the haematopoietic and immune systems highlights the importance of close collaboration between dermatology, haematology and immunology teams to enable the delivery of optimal multidisciplinary patient care.
In this chapter the cutaneous manifestations of malignant and benign haematological disease are reviewed, as well as skin disorders associated with primary and acquired immunodeficiency. The vast array of skin manifestations associated with disorders of the haematopoietic and immune systems highlights the importance of close collaboration between dermatology, haematology and immunology teams to enable the delivery of optimal multidisciplinary patient care.
Eosinophilic dermatosis of hematologic malignancy (EDHM) is a cutaneous manifestation seen in patients with hematoproliferative and lymphoproliferative disorders, most commonly chronic lymphocytic leukemia. This systematic review aimed to summarize the therapeutic interventions of EDHM. A comprehensive search yielded 71 studies, predominantly case reports and series. The most frequently reported modalities were systemic and topical corticosteroids, as well as treatment of the underlying malignancy. Responses to these treatments varied. Targeted therapies, including dupilumab and omalizumab, showed promise, as did other modalities such as montelukast, dapsone, doxycycline, and phototherapy. Higher‐quality studies should be conducted to facilitate higher‐quality management recommendations for EDHM.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.